Andrew Combs - 04 Feb 2025 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Chief Chemistry Officer
Signature
/s/ Krishna Vaddi, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
04 Feb 2025
Transactions value $
$0
Form type
4
Filing time
05 Feb 2025, 16:32:03
Previous filing
26 Dec 2024
Next filing
27 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Award $0 +175K $0.00 175K 04 Feb 2025 Common Stock 175K $1.11 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.